{"id":46845,"date":"2025-11-12T15:24:10","date_gmt":"2025-11-12T07:24:10","guid":{"rendered":"https:\/\/flcube.com\/?p=46845"},"modified":"2025-11-12T15:24:11","modified_gmt":"2025-11-12T07:24:11","slug":"novo-nordisk-announces-major-china-business-restructuring-effective-jan-1-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46845","title":{"rendered":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on <strong>1\u202fJanuary\u202f2026<\/strong>. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-structural-changes\">Key Structural Changes<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>New Division<\/th><th>Former Name<\/th><th>Core Focus<\/th><th>Strategic Actions<\/th><\/tr><\/thead><tbody><tr><td><strong>Insulin Business Division (IBD)<\/strong><\/td><td>Emerging Business Division (EBD)<\/td><td>Innovative insulin portfolio (e.g., NovoRapid, Tresiba)<\/td><td><strong>Divest<\/strong> all GLP\u20111\u2011related assets; double\u2011down on next\u2011gen insulin R&amp;D and market launch<\/td><\/tr><tr><td><strong>Diabetes &amp; Obesity Division (DOD)<\/strong><\/td><td>\u2013<\/td><td>Full\u2011scenario semaglutide business (Ozempic, Rybelsus) and obesity pipeline (Wegovy)<\/td><td>Consolidate GLP\u20111 leadership; expand obesity market share; integrate oral and injectable GLP\u20111 products<\/td><\/tr><tr><td><strong>Distribution &amp; Retail Division (DRD)<\/strong><\/td><td>\u2013<\/td><td>Channel optimization across primary\u2011level hospitals, VBP\u2011listed products, and e\u2011commerce<\/td><td>Act as \u201cterminal promoter\u201d for IBD and DOD; deepen hospital coverage; synchronize online\u2011offline retail<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rationale-amp-market-impact\">Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Insulin Focus:<\/strong> By spinning off GLP\u20111 assets, Novo Nordisk aims to protect its <strong>century\u2011long insulin leadership<\/strong> in China, a market projected to reach <strong>\u00a5300\u202fbillion<\/strong> in diabetes spend by 2028.<\/li>\n\n\n\n<li><strong>GLP\u20111 Consolidation:<\/strong> The DOD will become the single point of accountability for <strong>semaglutide<\/strong> (Ozempic, Rybelsus) and <strong>Wegovy<\/strong>, positioning the company to capture the rapidly expanding <strong>obesity<\/strong> segment, estimated at <strong>\u00a5120\u202fbillion<\/strong> in 2026.<\/li>\n\n\n\n<li><strong>Channel Moat:<\/strong> DRD\u2019s integrated hospital\u2011to\u2011retail model is intended to safeguard Novo Nordisk\u2019s <strong>volume\u2011based procurement (VBP)<\/strong> contracts and accelerate digital sales, a critical lever as China\u2019s healthcare system pivots toward online\u2011first distribution.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-timeline\">Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td>Official restructuring announcement<\/td><td>11\u202fNov\u202f2025<\/td><\/tr><tr><td>Organizational change effective<\/td><td>1\u202fJan\u202f2026<\/td><\/tr><tr><td>First post\u2011restructuring insulin product launch (next\u2011gen basal)<\/td><td>H2\u202f2026<\/td><\/tr><tr><td>Full integration of semaglutide portfolio under DOD<\/td><td>Q1\u202f2026<\/td><\/tr><tr><td>DRD rollout of unified online\u2011offline retail platform<\/td><td>Q3\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the restructuring timeline, product launches, and market expectations for Novo Nordisk\u2019s China operations. Actual results may differ due to risks including regulatory changes, competitive dynamics, and execution of the re\u2011organization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46855,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[39,4361,148,860,86],"class_list":["post-46845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-diabetes","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46845\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46845\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T07:24:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-12T07:24:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026\",\"datePublished\":\"2025-11-12T07:24:10+00:00\",\"dateModified\":\"2025-11-12T07:24:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845\"},\"wordCount\":347,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202.webp\",\"keywords\":[\"Diabetes\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46845#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46845\",\"name\":\"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202.webp\",\"datePublished\":\"2025-11-12T07:24:10+00:00\",\"dateModified\":\"2025-11-12T07:24:11+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46845\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46845#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46845","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026","og_description":"Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.","og_url":"https:\/\/flcube.com\/?p=46845","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T07:24:10+00:00","article_modified_time":"2025-11-12T07:24:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46845#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46845"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026","datePublished":"2025-11-12T07:24:10+00:00","dateModified":"2025-11-12T07:24:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46845"},"wordCount":347,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","keywords":["Diabetes","Hot targets","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46845#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46845","url":"https:\/\/flcube.com\/?p=46845","name":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46845#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","datePublished":"2025-11-12T07:24:10+00:00","dateModified":"2025-11-12T07:24:11+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) released an internal memorandum outlining a sweeping re\u2011organization of its China operations that will take effect on 1\u202fJanuary\u202f2026. The overhaul is designed to sharpen focus on its core insulin franchise, accelerate growth of GLP\u20111 therapies, and reinforce distribution capabilities across the country.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46845#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46845"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46845#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","width":1080,"height":608,"caption":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46845#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Announces Major China Business Restructuring Effective Jan\u202f1\u202f2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46845"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46845\/revisions"}],"predecessor-version":[{"id":46856,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46845\/revisions\/46856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46855"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}